Pharmacological Treatment - An Overview of Its Role in Managing Childhood Obesity
NCT ID: NCT07304141
Last Updated: 2025-12-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
128 participants
OBSERVATIONAL
2023-12-20
2025-12-12
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The aim of this sub-study is to evaluate the impact of liraglutide treatment on the trajectory of body mass index (BMI), including BMI according to International Obesity Task Force (IOTF) criteria and BMI standard deviation score (BMI SDS), as well as its effects on cardiovascular risk markers among children and adolescents treated with liraglutide in two Swedish regions. The study seeks to generate real-world evidence on the effectiveness of liraglutide in routine clinical practice.
Study Design
This is a retrospective, observational study based on medical records of children and adolescents who received multidisciplinary obesity care for at least one year and were treated with liraglutide during 2022-2023 at either the Pediatric Clinic in Region Halland or the Regional Childhood Obesity Center at Queen Silvia's Children's Hospital. The study is non-interventional and does not introduce any additional risks beyond standard clinical care. Participation was voluntary, with informed consent obtained from legal guardians and assent from children.
Participants
Eligible participants include children and adolescents who:
Were enrolled in multidisciplinary obesity care for at least one year
Received liraglutide treatment during 2022-2023 at one of the study sites
Were invited to participate either during clinical visits or via written invitation
Data on comorbidities, including neuropsychiatric diagnoses, were also collected to assess potential confounding factors.
Data Collection
Data were extracted retrospectively from medical records and include:
Demographics: sex, age
Anthropometrics: height, weight, BMI, BMI SDS, BMI according to IOTF criteria
Treatment details: titration period, maximum tolerated dose, and treatment outcomes at 3-6, 12, 18.
Metabolic parameters: blood pressure, lipid profile, fasting glucose, and HbA1c
Comorbidities: neuropsychiatric and other relevant diagnoses
All data were anonymized and handled in accordance with Swedish data protection regulations.
Statistical Analysis
Descriptive Statistics:
Continuous variables (e.g., age, BMI, metabolic parameters) will be summarized using mean ± standard deviation (SD) or median with interquartile range (IQR), as appropriate.
Categorical variables (e.g., sex, comorbidities) will be summarized using counts and percentages.
Treatment effects at 3-6, 12, 18, and 24 months will be evaluated using appropriate repeated measures models, accounting for potential confounders such as age, sex, baseline BMI, and comorbidities.
Handling of Missing Data:
Missing data will be assessed for patterns and mechanisms.
Multiple imputation or sensitivity analyses may be performed depending on the proportion and nature of missing values.
Statistical Collaboration:
All analyses will be conducted in collaboration with an experienced statistician.
The analysis plan and results will be reviewed and validated by both the statistician and study supervisors.
Ethical Considerations
Participation was voluntary and did not affect ongoing clinical care.
Informed consent was obtained from legal guardians, with assent from children.
Data were anonymized and managed according to Swedish data protection laws.
The study was retrospective and non-interventional; no specific approval from the Swedish Medical Products Agency was required.
All procedures adhere to the ethical principles of the Declaration of Helsinki.
Dissemination
Results will be disseminated through a peer-reviewed publication and scientific conference presentations. Sub-study III is expected to be finalized in 2026.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
The study included adolescents aged 10-18 years with obesity who were offered liraglutide treatment
Liraglutide 3 mg (Saxenda)
This is a retrospective observational study of adolescents aged 10-18 years with obesity who were offered liraglutide treatment at the Pediatric Clinic in Region Halland and at the Regional Childhood Obesity Center, Queen Silvia's Children's Hospital, Sahlgrenska University Hospital.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Liraglutide 3 mg (Saxenda)
This is a retrospective observational study of adolescents aged 10-18 years with obesity who were offered liraglutide treatment at the Pediatric Clinic in Region Halland and at the Regional Childhood Obesity Center, Queen Silvia's Children's Hospital, Sahlgrenska University Hospital.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Provided consent to participate
* Participants with short treatment duration, early adverse effects, or who proceeded to surgery are also included in baseline data
Exclusion Criteria
* Craniopharyngioma
* Syndromic obesity / monogenic obesity
10 Years
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Göteborg University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Lovisa Sjogren
MD PhD
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
the Regional Childhood Obesity Center, Queen Silvia's Children's Hospital.
Gothenburg, , Sweden
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Dnr 2023-04013-01
Identifier Type: -
Identifier Source: org_study_id